Go to content
Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 20 okt 2014 - 07:36
Statutaire naam Galapagos NV
Titel Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
Bericht Mechelen, Belgium; 20 October 2014 - Galapagos NV (Euronext: GLPG) discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October. Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84.